share_log

Emergent BioSolutions | 10-Q: Q2 2024 Earnings Report

Emergent BioSolutions | 10-Q: Q2 2024 Earnings Report

Emergent BioSolutions | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 02:33

Moomoo AI 已提取核心信息

Emergent BioSolutions reported Q2 2024 revenues of $254.7M, down 25% YoY, with a net loss of $283.1M compared to a $261.4M loss in Q2 2023. Commercial product sales declined 13% to $120M, while MCM product sales fell 61% to $63.4M. Services revenue increased 122% to $64.7M, including a $50M arbitration settlement with Janssen.The company recorded a $27.2M impairment charge related to facility closures and recognized a $40M loss from the planned sale of its Baltimore-Camden facility to Bora Pharmaceuticals. Operating expenses decreased 27% to $458.2M, primarily due to lower impairment charges compared to Q2 2023. The company implemented restructuring plans to reduce workforce and streamline operations.As of June 30, 2024, Emergent had $69.7M in cash and $863.8M in total debt. The company faces substantial going concern uncertainty due to upcoming debt maturities and covenant requirements. Management is pursuing strategic alternatives including asset sales, with the recent $75M sale of RSDL to SERB Pharmaceuticals and pending $30M sale of the Baltimore-Camden facility.
Emergent BioSolutions reported Q2 2024 revenues of $254.7M, down 25% YoY, with a net loss of $283.1M compared to a $261.4M loss in Q2 2023. Commercial product sales declined 13% to $120M, while MCM product sales fell 61% to $63.4M. Services revenue increased 122% to $64.7M, including a $50M arbitration settlement with Janssen.The company recorded a $27.2M impairment charge related to facility closures and recognized a $40M loss from the planned sale of its Baltimore-Camden facility to Bora Pharmaceuticals. Operating expenses decreased 27% to $458.2M, primarily due to lower impairment charges compared to Q2 2023. The company implemented restructuring plans to reduce workforce and streamline operations.As of June 30, 2024, Emergent had $69.7M in cash and $863.8M in total debt. The company faces substantial going concern uncertainty due to upcoming debt maturities and covenant requirements. Management is pursuing strategic alternatives including asset sales, with the recent $75M sale of RSDL to SERB Pharmaceuticals and pending $30M sale of the Baltimore-Camden facility.
Emergent BioSolutions报告2024年第二季度营业收入为25470万美元，同比下降25%，净亏损为28310万美元，较2023年第二季度的26140万美元亏损有所增加。商业产品销售下降了13%，至12000万美元，而MCm产品销售则下降了61%，至6340万美元。服务营业收入增长了122%，达到6470万美元，其中包括与Janssen达成的5000万美元仲裁和解。 公司记录了2720万美元的资产减值费用，涉及设施关闭，并确认了计划将其巴尔的摩-堪登设施出售给博尔制药公司的4000万美元亏损。营业费用下降了27%，至45820万美元，主要是由于与2023年第二季度相比，减值费用...展开全部
Emergent BioSolutions报告2024年第二季度营业收入为25470万美元，同比下降25%，净亏损为28310万美元，较2023年第二季度的26140万美元亏损有所增加。商业产品销售下降了13%，至12000万美元，而MCm产品销售则下降了61%，至6340万美元。服务营业收入增长了122%，达到6470万美元，其中包括与Janssen达成的5000万美元仲裁和解。 公司记录了2720万美元的资产减值费用，涉及设施关闭，并确认了计划将其巴尔的摩-堪登设施出售给博尔制药公司的4000万美元亏损。营业费用下降了27%，至45820万美元，主要是由于与2023年第二季度相比，减值费用降低。公司实施了重组计划，以减少劳动力并简化运营。 截至2024年6月30日，Emergent拥有6970万美元现金和86380万美元的总债务。由于即将到期的债务和契约要求，公司面临重大持续经营的不确定性。管理层正在寻求包括资产出售在内的战略替代方案，最近将RSDL以7500万美元的价格出售给SERb制药公司，并计划将巴尔的摩-堪登设施以3000万美元的价格出售。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    坎伯兰药业
    CPIX
    -- 4.410
    IM Cannabis
    IMCC
    -- 1.839
    Journey Medical
    DERM
    -- 6.110
    Quantum BioPharma
    QNTM
    -- 8.560
    Citius Oncology
    CTOR
    -- 0.665
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点